Neuraminidase inhibitors for the treatment and prophylaxis of influenza: public consultation opens
Current recommendations in EU Member States in support of the use of neuraminidase inhibitors as a treatment or prophylaxis for influenza disease are appropriate, but the antivirals are being underutilised.
Current recommendations on the use of the neuraminidase inhibitors oseltamivir and zanamivir for the treatment and prophylaxis of influenza disease are appropriate, finds a new expert opinion from ECDC, which today opens for public consultation.
The review of recent systematic reviews and meta-analyses on the use of neuraminidase inhibitors for prevention and treatment of influenza finds that the studies presented strengthen the evidence base for the use of these antiviral treatments.
Continued debate surrounding the effectiveness and safety of these antivirals has led to some uncertainty within the public health community regarding the antivirals’ potential benefits as a treatment option or as prophylaxis for influenza disease. As a result, the public health benefits may be being missed.
The ECDC expert opinion demonstrates that there is evidence for use of neuraminidase inhibitors for treatment and prophylaxis of influenza. It also highlights the importance of further studies and the urgent need for the development of new antivirals with greater efficacy.
The report is open for public consultation and all comments are welcome. They will be considered and addressed by the authors prior to publication of the final report.
How to submit contributions:
Note that the comments received must clearly state the identity of the contributor (i.e. country, name and surname, and affiliation in the case of contributions from individuals; or name of organisation in the case of contributions on behalf of an organisation). Contributors are kindly asked to mention the respective line and page numbers of the document to which their comment(s) refer. Please read the guidelines for submission of contributions and kindly note that only contributions following ECDC guidelines will be considered.
For more information on the processing of your personal data in the context of this consultation, read the specific privacy statement.
Deadline: 16 March 2016
*Users of Internet Explorer may encounter problems when opening this form. If you experience difficulties, please save the document as a compatible Word file before opening. To save, right click on the link and choose 'Save target as'.If you are requested to provide a 'username' and 'password', click 'Cancel'. The form will open.
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more
Epidemiological update: Review of influenza season 2016–2017 in the EU/EEA
The influenza season 2016–2017 has now come to an end in Europe. In week 17/2017, all EU/EEA countries reported low influenza activity and the positivity rate (proportion of influenza virus positives among all tested specimens) falling below the 10% benchmark to 9.9%. For the previous six weeks, almost all EU/EEA countries had reported low influenza activity.Read more